Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment
HS was prognostic for RFS and OS in patients with resected stage III pMMR/MSS CC and associated with a trend toward improved RFS with the addition of cetuximab to adjuvant FOLFOX. Conversely, cetuximab seems detrimental in patients with GA tumors. These data may help to improve patient selection in future adjuvant clinical trials testing anti-EGFR therapies.
Authors
- Claire Mulot
- Simon Garinet (ORCID: https://orcid.org/0000-0002-2182-8793)
- Julien Taı̈eb (ORCID: https://orcid.org/0000-0002-9955-4753)
- Marine Sroussi (ORCID: https://orcid.org/0000-0003-3545-5518)
- Maria Vittoria Ambrosini (ORCID: https://orcid.org/0000-0001-9540-7679)
- Sophie Mouillet‐Richard (ORCID: https://orcid.org/0000-0002-8950-1949)
- C. Lepage
- Hélène Blons (ORCID: https://orcid.org/0000-0002-0572-8426)
- Delphine Le Corre
- F. Pietrantonio
- Pierre Laurent‐Puig (ORCID: https://orcid.org/0000-0001-8475-5459)
Institutions
- Délégation Paris 5 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université de Bourgogne (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Sorbonne Paris Cité (FR)
- Centre de Recherche des Cordeliers (FR)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105857
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00